T. Rowe Price Associates
ZNTL icon

T. Rowe Price Associates’s Zentalis Pharmaceuticals ZNTL Stock Holding History

T. Rowe Price Associates’s Portfolio ZNTL Stock Details ZNTL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$200K Buy
+41,049
New +$164K ﹤0.01% 3006
2025
Q3 		– Sell
-41,454
Closed -$49K – 3134
2025
Q2 		$49K Sell
41,454
-28,231
-41% -$37.2K ﹤0.01% 3011
2025
Q1 		$111K Sell
69,685
-910,170
-93% -$1.96M ﹤0.01% 2800
2024
Q4 		$2.97M Sell
979,855
-57,056
-6% -$187K ﹤0.01% 1461
2024
Q3 		$3.82M Buy
1,036,911
+113,010
+12% +$411K ﹤0.01% 1380
2024
Q2 		$3.78M Sell
923,901
-2,565,808
-74% -$28.7M ﹤0.01% 1308
2024
Q1 		$55M Buy
3,489,709
+585,644
+20% +$8.06M 0.01% 708
2023
Q4 		$44M Buy
2,904,065
+188,466
+7% +$2.75M 0.01% 747
2023
Q3 		$54.5M Buy
2,715,599
+31,247
+1% +$793K 0.01% 653
2023
Q2 		$75.7M Buy
2,684,352
+484,183
+22% +$11.6M 0.01% 588
2023
Q1 		$37.8M Buy
2,200,169
+23,469
+1% +$475K 0.01% 759
2022
Q4 		$43.8M Sell
2,176,700
-41,040
-2% -$883K 0.01% 698
2022
Q3 		$48M Sell
2,217,740
-2,080,811
-48% -$56.9M 0.01% 658
2022
Q2 		$121M Buy
4,298,551
+100,371
+2% +$2.66M 0.02% 609
2022
Q1 		$194M Sell
4,198,180
-184,701
-4% -$9.96M 0.02% 534
2021
Q4 		$368M Buy
4,382,881
+652,456
+17% +$50.5M 0.03% 408
2021
Q3 		$249M Buy
3,730,425
+470,857
+14% +$27.2M 0.02% 476
2021
Q2 		$173M Buy
3,259,568
+2,175,322
+201% +$117M 0.02% 604
2021
Q1 		$47M Sell
1,084,246
-9,780
-0.9% -$421K ﹤0.01% 1026
2020
Q4 		$56.8M Sell
1,094,026
-11,994
-1% -$541K 0.01% 919
2020
Q3 		$36.2M Sell
1,106,020
-81,546
-7% -$2.86M ﹤0.01% 977
2020
Q2 		$57M Buy
+1,187,566
New +$45.5M 0.01% 808

Other funds holding ZNTL

5VM
5AM Venture Management San Francisco, California $288M AUM 313.93% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
SCM
Squadron Capital Management Westmont, Illinois $322M AUM
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $1.1B AUM 197.64% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return

T. Rowe Price Associates's ZNTL Position: Q2 2026 in Review

T. Rowe Price Associates opened a new position in Zentalis Pharmaceuticals (ZNTL) in Q2 2026: 41,049 shares worth $200K. The stake represents ﹤0.01% of the portfolio and ranks #3006 among its holdings. This is a return to the name: T. Rowe Price Associates previously reported a position in ZNTL as recently as Q2 2025.

T. Rowe Price Associates first reported a position in ZNTL in Q2 2020 and has held it in 22 quarters since. The position peaked at $368M in Q4 2021. 114 funds tracked by Wall St. Rank hold ZNTL as of Q2 2026.

  • T. Rowe Price Associates held 41,049 shares of Zentalis Pharmaceuticals worth $200K as of Q2 2026.
  • Zentalis Pharmaceuticals was a new T. Rowe Price Associates position in Q2 2026.
  • Zentalis Pharmaceuticals made up ﹤0.01% of T. Rowe Price Associates's portfolio in Q2 2026, its #3006 holding.
  • T. Rowe Price Associates first reported a position in Zentalis Pharmaceuticals in Q2 2020 and has held it in 22 quarters since.
  • T. Rowe Price Associates's Zentalis Pharmaceuticals position peaked at $368M in Q4 2021.
  • 114 funds tracked by Wall St. Rank held Zentalis Pharmaceuticals as of Q2 2026.

Based on T. Rowe Price Associates's 13F filing for Q2 2026, filed 14 Aug 2026.